KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Steris (STE) Short-Term Debt issuances (2018 - 2025)

Steris has reported Short-Term Debt issuances over the past 8 years, most recently at -$4.3 million for Q3 2025.

  • Quarterly results put Short-Term Debt issuances at -$4.3 million for Q3 2025, up 95.31% from a year ago — trailing twelve months through Dec 2025 was -$162.1 million (up 59.78% YoY), and the annual figure for FY2025 was -$446.3 million, down 345.92%.
  • Short-Term Debt issuances for Q3 2025 was -$4.3 million at Steris, up from -$30.5 million in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for STE hit a ceiling of $535.7 million in Q3 2023 and a floor of -$253.2 million in Q2 2024.
  • Median Short-Term Debt issuances over the past 5 years was -$30.5 million (2025), compared with a mean of -$15.9 million.
  • Biggest five-year swings in Short-Term Debt issuances: soared 1728.26% in 2021 and later crashed 490.83% in 2023.
  • Steris' Short-Term Debt issuances stood at -$138.8 million in 2021, then surged by 184.63% to $117.4 million in 2022, then crashed by 206.87% to -$125.5 million in 2023, then surged by 120.63% to $25.9 million in 2024, then crashed by 116.6% to -$4.3 million in 2025.
  • The last three reported values for Short-Term Debt issuances were -$4.3 million (Q3 2025), -$30.5 million (Q2 2025), and -$127.3 million (Q1 2025) per Business Quant data.